Skip to main content

Advertisement

Log in

Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget’s disease of bone

  • CASE REPORT
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. ES Siris GD Roodman (2003) Paget’s disease of bone MJ Favus (Eds) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism American Society for Bone and Mineral Research Washington DC 495–506

    Google Scholar 

  2. E Siris RS Weinstein R Altman JM Conte M Favus A Lombardi K Lyles H McIlwain WA Murphy SuffixJr C Reda R Rude M Seton R Tiegs D Thompson JR Tucci AJ Yates M Zimering (1996) ArticleTitleComparative study of alendronate vs etidronate for the treatment of Paget s disease of bone. J Clin Endocrinal Metab 81 961–967 Occurrence Handle1:CAS:528:DyaK28Xhs1agsrk%3D

    CAS  Google Scholar 

  3. IR Reid GC Nicholson RS Weinstein DJ Hosking T Cundy MA Kotowicz WA Murphy SuffixJr S Yeap S Dufresne A Lombardi TA Musliner DE Thompson AJ Yates (1996) ArticleTitleBiochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo controlled trial. Am J Med 171 341–348

    Google Scholar 

  4. A Lombardi (1999) ArticleTitleTreatment of Paget s disease of bone with alendronate. Bone 24 59S–61S Occurrence Handle1:CAS:528:DyaK1MXjtVGitLg%3D

    CAS  Google Scholar 

  5. PL Selby MWJ Davie SH Ralston MD Stone (2002) ArticleTitleGuidelines on the management of Paget s disease of bone. Bone 31 366–373 Occurrence Handle1:STN:280:DC%2BD38vntVCrsg%3D%3D

    CAS  Google Scholar 

  6. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud (1996) ArticleTitleRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535–1541 Occurrence Handle10.1016/S0140-6736(96)07088-2 Occurrence Handle1:CAS:528:DyaK2sXisFCktQ%3D%3D Occurrence Handle8950879

    Article  CAS  PubMed  Google Scholar 

  7. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix (1998) ArticleTitleEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280 2077–2082 Occurrence Handle1:CAS:528:DyaK1MXjsVWruw%3D%3D

    CAS  Google Scholar 

  8. K Kushida M Shiraki T Nakamura H Kishimoto H Morii K Yamamoto K Kaneda M Fukunaga T Inoue M Nakashima H Orimo (2004) ArticleTitleAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow up study. J Bone Miner Metab 22 462–468 Occurrence Handle10.1007/s00774-004-0508-0 Occurrence Handle1:CAS:528:DC%2BD2cXmslCit7c%3D

    Article  CAS  Google Scholar 

  9. ES Siris RE Canfield TP Jacobs KE Stoddart PJ Spector (1981) ArticleTitleClinical and biochemical effects of EHDP in Paget’s disease of bone: pattern of response to initial treatment and to long therapy. Metab Bone Dis Relat Res 3 301–308 Occurrence Handle1:STN:280:BiyC28nls10%3D

    CAS  Google Scholar 

  10. PD Delmas MC Chapuy E Vignon S Charhon D Briancon C Alexandre C Edouard PJ Meunier (1982) ArticleTitleLong term effects of dichloromethylene diphosphonate in Paget s disease of bone. J Clin Endocrinal Metab 54 837–844 Occurrence Handle1:STN:280:Bi2C2c3ptFw%3D

    CAS  Google Scholar 

  11. ST Harris RM Neer GV Segre AJ Petkau GL Tully Suffix3rd M Daly JT Potts SuffixJr (1982) ArticleTitleSecondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget’s disease J Clin Endocrinal Metab 55 1100–1107 Occurrence Handle1:STN:280:BiyD3s7htVM%3D

    CAS  Google Scholar 

  12. S Adami N Zamberlan M Mian R Dorizzi M Rossini B Braga D Gatti F Bertoldo V Locascio (1994) ArticleTitleDuration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget s disease of bone. Bone Miner 25 75–82 Occurrence Handle1:CAS:528:DyaK2cXlslSntLk%3D

    CAS  Google Scholar 

  13. MEMW Eekhoff AH Zwinderman DMAD Haverkort SCLM Cremers NAT Hamdy SE Papapoulou (2003) ArticleTitleDeterminants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate therapy. Bone 33 831–838 Occurrence Handle10.1016/j.bone.2003.03.001 Occurrence Handle1:CAS:528:DC%2BD3sXovVemt7w%3D

    Article  CAS  Google Scholar 

  14. ES Siris (1999) ArticleTitleGoals of treatment for Paget s disease of bone. J Bone Miner Res 14 IssueIDs2 49–52

    Google Scholar 

  15. SA Khan S Vasikaran EV McCloskey MNC Benéton S Rogers L Coulton J Orgee G Coombes JA Kanis (1997) ArticleTitleAlendronate in the treatment of Paget’s disease of bone Bone 20 263–271 Occurrence Handle10.1016/S8756-3282(96)00364-X Occurrence Handle1:CAS:528:DyaK2sXit12qsbw%3D Occurrence Handle9071478

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Junichi Takada.

About this article

Cite this article

Takada, J., Iba, K. & Yamashita, T. Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget’s disease of bone. J Bone Miner Metab 23, 333–336 (2005). https://doi.org/10.1007/s00774-005-0609-4

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-005-0609-4

Keywords

Navigation